Biotech Scan
Biotech Scan
Life sciences tools selloff deepening (DHR RSI 29, MDT RSI 27, TMO RSI 33, A RSI 31) while BNTX capitulates at RSI 23 with -23.3% 30D; MRNA surges +38.4% 30D (+89.3% 3M) on the opposite side of the mRNA trade; large-cap pharma (ABBV, AMGN, REGN) stays boring and stable as the sector anchor.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟡 MIXED — Life sciences tools (DHR, MDT, TMO, A) remain oversold as a group, BNTX still in mRNA capitulation at RSI 23, while MRNA extends its monster run (+89.3% 3M); large-cap pharma boring and stable; surgical/medtech (ISRG, DXCM) drifting lower |
| Leaders | MRNA (+38.4% 30D, +89.3% 3M), EDIT (+49.2% 30D), PTGX (+16.2% 30D), NTLA (+12.3% 30D), VRTX (+8.2% 30D) |
| Laggards | DNA (-32.2% 30D), BNTX (-23.3% 30D, RSI 23), NVO (-20.6% 30D), DHR (-11.3% 30D, RSI 29), MDT (-11.1% 30D, RSI 27) |
Price Table (2026-03-11)
| Stock | Price | RSI | SMA20 | SMA50 | SMA200 | vs SMA20 | vs SMA50 | Trend | 7D% | 30D% | Signal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ETFs | — | — | — | — | — | — | — | — | — | — | — |
| XBI | $127.43 | 54 | $125.81 | $125.38 | $104.85 | +1.3% | +1.6% | strong-up | +1.8% | +2.2% | 🟢 Healthy |
| IBB | $172.27 | 49 | $172.94 | $172.76 | $151.62 | -0.4% | -0.3% | weak-down | +0.4% | -0.3% | 🟡 Neutral |
| IBBQ | $29.56 | 51 | $29.60 | $29.29 | $25.46 | -0.1% | +0.9% | strong-up | +0.5% | +0.4% | 🟡 Neutral |
| LABU | $171.50 | 53 | $166.58 | $168.15 | $112.23 | +3.0% | +2.0% | strong-up | +5.0% | +5.0% | 🟢 Healthy |
| Large-Cap Pharma | — | — | — | — | — | — | — | — | — | — | — |
| ABBV | $227.75 | 50 | $229.06 | $224.46 | $211.85 | -0.6% | +1.5% | strong-up | -2.9% | +3.1% | 🟡 Neutral |
| GILD | $145.98 | 51 | $149.34 | $139.06 | $120.96 | -2.2% | +5.0% | strong-up | +0.3% | -6.3% | 🟡 Neutral |
| AMGN | $377.92 | 57 | $376.19 | $353.82 | $309.98 | +0.5% | +6.8% | strong-up | -0.2% | +3.8% | 🟢 Healthy |
| REGN | $775.25 | 51 | $780.12 | $770.56 | $643.56 | -0.6% | +0.6% | strong-up | -0.8% | -0.4% | 🟡 Neutral |
| BIIB | $188.41 | 51 | $190.99 | $183.42 | $154.67 | -1.3% | +2.7% | strong-up | +0.8% | -1.5% | 🟡 Neutral |
| LLY | $999.10 | 45 | $1,019.73 | $1,041.66 | $882.53 | -2.0% | -4.1% | weak-down | +0.2% | -1.4% | 🟡 Neutral — GLP-1 king drifting |
| VRTX | $499.17 | 60 | $475.96 | $468.21 | $437.56 | +4.9% | +6.6% | strong-up | +5.0% | +8.2% | 🟢 Strong — leading pharma |
| mRNA | — | — | — | — | — | — | — | — | — | — | — |
| MRNA | $56.08 | 64 | $50.20 | $44.19 | $31.56 | +11.7% | +26.9% | strong-up | +1.9% | +38.4% | 🟠 Extended — massive rally |
| NVO | $38.72 | 34 | $42.57 | $50.78 | $55.97 | -9.0% | -23.7% | strong-down | +1.4% | -20.6% | 🔴 Breakdown |
| BNTX | $83.89 | 23 | $105.83 | $106.23 | $104.79 | -20.7% | -21.0% | down | -17.4% | -23.3% | 🔴 Capitulation |
| Gene Editing / Gene Therapy | — | — | — | — | — | — | — | — | — | — | — |
| CRSP | $49.94 | 41 | $55.36 | $54.29 | $55.53 | -9.8% | -8.0% | strong-down | -11.6% | +3.4% | 🟡 Pullback after run |
| NTLA | $13.47 | 52 | $13.14 | $12.39 | $12.39 | +2.5% | +8.7% | strong-up | -3.7% | +12.3% | 🟡 Recovering |
| BEAM | $26.08 | 44 | $27.75 | $28.74 | $23.37 | -6.0% | -9.2% | weak-down | -6.5% | +0.4% | 🟡 Neutral |
| EDIT | $2.64 | 67 | $1.99 | $2.03 | $2.54 | +32.7% | +30.0% | up | +21.6% | +49.2% | 🟠 Near Overbought |
| LEGN | $19.56 | 56 | $18.59 | $19.60 | $29.72 | +5.2% | -0.2% | strong-down | +10.1% | +5.5% | 🟢 Recovering |
| SRPT | $17.66 | 47 | $17.59 | $19.79 | $21.00 | +0.4% | -10.8% | strong-down | +9.8% | -1.7% | 🟡 Bouncing |
| Genomics / Diagnostics | — | — | — | — | — | — | — | — | — | — | — |
| ALNY | $322.38 | 42 | $326.04 | $351.76 | $391.69 | -1.1% | -8.4% | strong-down | +0.2% | +0.0% | 🟡 Neutral |
| BMRN | $60.89 | 54 | $61.05 | $59.07 | $56.62 | -0.3% | +3.1% | strong-up | +3.1% | +1.0% | 🟡 Neutral |
| INCY | $96.02 | 39 | $99.73 | $102.02 | $88.57 | -3.7% | -5.9% | weak-down | -1.7% | -2.9% | 🟡 Approaching Oversold |
| ILMN | $122.35 | 42 | $122.97 | $134.21 | $111.49 | -0.5% | -8.8% | weak-down | -7.3% | +5.1% | 🟡 Neutral |
| EXAS | $103.37 | 56 | $103.37 | $102.68 | $72.41 | +0.0% | +0.7% | strong-up | -0.1% | -0.1% | 🟡 Neutral |
| IONS | $75.66 | 38 | $80.70 | $80.96 | $63.05 | -6.2% | -6.6% | weak-down | -3.6% | -10.3% | 🟡 Approaching Oversold |
| DXCM | $67.79 | 38 | $71.12 | $70.65 | $73.32 | -4.7% | -4.1% | strong-down | -5.5% | -0.5% | 🟡 Approaching Oversold |
| Surgical / MedTech | — | — | — | — | — | — | — | — | — | — | — |
| ISRG | $485.85 | 40 | $495.86 | $521.04 | $512.20 | -2.0% | -6.8% | down | -3.2% | -2.1% | 🟡 Weakening |
| MDT | $89.89 | 27 | $96.72 | $98.40 | $93.40 | -7.1% | -8.6% | down | -6.6% | -11.1% | 🟢 Oversold |
| Tools / Services | — | — | — | — | — | — | — | — | — | — | — |
| DHR | $195.22 | 29 | $207.94 | $221.49 | $209.81 | -6.1% | -11.9% | down | -4.6% | -11.3% | 🟢 Oversold |
| TMO | $495.61 | 33 | $511.29 | $563.35 | $512.01 | -3.1% | -12.0% | down | -2.3% | -6.0% | 🟡 Approaching Oversold |
| A | $115.43 | 31 | $122.37 | $132.00 | $129.59 | -5.7% | -12.6% | down | -4.0% | -10.5% | 🟢 Approaching Oversold |
| IQV | $170.93 | 39 | $171.65 | $206.15 | $194.43 | -0.4% | -17.1% | down | -3.1% | -3.5% | 🟡 Weakening |
| Small-Cap / Speculative | — | — | — | — | — | — | — | — | — | — | — |
| PTGX | $97.05 | 67 | $88.06 | $85.34 | $70.78 | +10.2% | +13.7% | strong-up | +4.5% | +16.2% | 🟠 Near Overbought |
| DNA | $6.34 | 34 | $8.19 | $8.82 | $10.40 | -22.6% | -28.2% | strong-down | -8.0% | -32.2% | 🔴 Breakdown |
| RXRX | $3.44 | 40 | $3.58 | $4.08 | $4.83 | -4.0% | -15.6% | strong-down | -7.5% | -7.3% | 🟡 Weak |
| RARE | $22.84 | 48 | $22.35 | $23.31 | $30.21 | +2.2% | -2.0% | strong-down | +4.4% | -4.4% | 🟡 Neutral |
| BLUE | N/A | — | — | — | — | — | — | — | — | — | — No Data |
| SWTX | N/A | — | — | — | — | — | — | — | — | — | — No Data |
Tier Analysis
Oversold (RSI < 30) — Capitulation Territory
BNTX (RSI 23, -23.3% 30D, -20.7% below SMA20) — mRNA sentiment washout continues unabated. Price at $83.89 vs SMA20 of $105.83 is an enormous gap. The -17.4% 7D acceleration confirms active capitulation. Down -32.4% from 52-week high. Either a deep-value contrarian entry or thesis collapse on post-COVID mRNA demand. MDT (RSI 27, -11.1% 30D, -7.1% below SMA20) — Medtronic rarely sees RSI sub-30. At $89.89 down -9.2% 3M and -8.6% below SMA50, this looks like forced selling or rotation pressure rather than fundamental deterioration. Death cross not triggered — still above SMA200. DHR (RSI 29, -11.3% 30D, -6.1% below SMA20) — Danaher life sciences tools bellwether entering oversold. Quality compounder at $195.22, down -15.9% 3M and -11.9% below SMA50. When DHR hits RSI 29, historically that's been a strong entry signal.
Approaching Oversold (RSI 30-40) — Watch Closely
A (RSI 31, -10.5% 30D, -19.1% 3M) — Agilent tracking DHR lower. At -12.6% below SMA50 and -10.9% below SMA200, the tools de-rating is deep. TMO (RSI 33, -6.0% 30D, -14.3% 3M) — Thermo Fisher deepening alongside DHR, now -12.0% below SMA50. Life sciences tools selloff is sector-wide. NVO (RSI 34, -20.6% 30D, -53.1% from 52-week high) — Novo Nordisk GLP-1 giant in secular decline. Death cross active, -23.7% below SMA50. Small +1.4% 7D bounce, but no stabilization. DNA (RSI 34, -32.2% 30D, -36.0% 3M, -63.9% from high) — Ginkgo in freefall, no stabilization. Death cross, -28.2% below SMA50. DXCM (RSI 38, -0.5% 30D, -24.7% from high) — DexCom drifting, -5.5% 7D. Death cross active. GLP-1 overhang on diabetes devices. IONS (RSI 38, -10.3% 30D) — Ionis antisense platform weakening, -6.6% below SMA50. INCY (RSI 39, -2.9% 30D) — Incyte drifting lower. IQV (RSI 39, -3.5% 30D, -24.4% 3M) — IQVIA sustained downtrend, -17.1% below SMA50 is severe. RXRX (RSI 40, -24.9% 3M, -52.1% from high) — Recursion AI-bio play still bleeding. ISRG (RSI 40, -2.1% 30D, -19.6% from high) — Intuitive Surgical drifting toward oversold, -6.8% below SMA50. Watch for RSI <35 entry.
Neutral (RSI 40-55) — Holding Ground
Large-cap pharma cluster: ABBV (RSI 50), REGN (RSI 51), BIIB (RSI 51), AMGN (RSI 57), GILD (RSI 51), LLY (RSI 45) — all within a tight 45-57 RSI band, near SMA20s, golden crosses intact. This group is doing what defensive pharma should: boring, stable, thesis intact. LLY at $999.10 only -1.4% 30D vs NVO's -20.6% — massive divergence continues. Also here: ALNY (RSI 42), BEAM (RSI 44), CRSP (RSI 41), ILMN (RSI 42), SRPT (RSI 47), RARE (RSI 48), NTLA (RSI 52), EXAS (RSI 56), BMRN (RSI 54), LEGN (RSI 56), LABU (RSI 53), XBI (RSI 54), IBB (RSI 49), IBBQ (RSI 51).
Extended (RSI > 60) — Don't Chase
EDIT (RSI 67, +49.2% 30D, +32.7% above SMA20) — Massively extended on a sub-$3 stock. At $2.64, the +49.2% 30D move on a stock -41.8% from its 52-week high screams dead-cat bounce. Still below SMA200 — death cross active. PTGX (RSI 67, +16.2% 30D, +10.2% above SMA20) — Protagen clinical-stage autoimmune play near 52-week highs (-1.2% from high). Golden cross intact, strong-up trend. More fundamentally grounded than EDIT but still extended. MRNA (RSI 64, +38.4% 30D, +89.3% 3M, +11.7% above SMA20) — The mRNA comeback monster. MRNA surging while BNTX capitulates. At $56.08, golden cross intact and only -5.8% from 52-week high. Massive +26.9% above SMA50 and +77.7% above SMA200 — parabolic. Don't chase here. VRTX (RSI 60, +8.2% 30D, +4.9% above SMA20) — Vertex quietly leading. Only -4.0% from 52-week high. Quality franchise trending right, golden cross intact.
Entry Zones
| Stock | Entry Zone | Thesis |
|---|---|---|
| ✅ DHR | $185-$200 | RSI 29, life sciences tools bellwether. Quality compounder -15.9% 3M, -11.9% below SMA50. |
| ✅ MDT | $85-$92 | RSI 27, defensive medtech oversold. Rarely this cheap — rotation-driven selloff. |
| 🔍 BNTX | $75-$85 | RSI 23 capitulation. mRNA thesis needs validation — cycle trough or structural decline? |
| 🔍 TMO | $480-$500 | RSI 33, tracking DHR in tools selloff. -12.0% below SMA50. Quality at -14.3% 3M. |
| 🔍 A | $110-$118 | RSI 31, approaching oversold. Life sciences tools sector-wide de-rating. |
| 🔍 NVO | $35-$40 | RSI 34, -53% from highs, death cross active. GLP-1 mega-theme under deep pressure. |
| 🔍 ISRG | $460-$490 | RSI 40, surgical robotics monopoly weakening. Watch for RSI <35 trigger. -19.6% from high. |
| 🔍 DXCM | $62-$68 | RSI 38, -24.7% from high. Death cross. GLP-1 overhang on diabetes devices. |
| 📈 LLY | $950-$1,000 | RSI 45, GLP-1 king holding far better than NVO (-1.4% 30D vs -20.6%). Weak-down trend but golden cross intact. |
| 📈 LEGN | $18-$21 | RSI 56, recovering from -56.8% capitulation. CAR-T play showing momentum (+10.1% 7D, +5.5% 30D). |
| 📈 CRSP | $45-$52 | RSI 41, gene editing leader. Pulled back -11.6% 7D — death cross caution but +3.4% 30D. |
| 🔍 RARE | $20-$24 | RSI 48, -36.9% 3M, -46.1% from highs. Rare disease pipeline optionality at deep discount. |
| ⚠️ EDIT | >$2.50 | RSI 67, +49.2% 30D — massively extended dead-cat bounce. Do not chase. |
| ⚠️ PTGX | >$90 | RSI 67, +16.2% 30D — extended near 52-week highs. |
| ⚠️ MRNA | >$50 | RSI 64, +38.4% 30D, +89.3% 3M — parabolic. Don't chase; wait for consolidation. |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| ✅ STRONG BUY | DHR | RSI 29, quality compounder -15.9% 3M. Life sciences tools bellwether at oversold. |
| ✅ STRONG BUY | MDT | RSI 27, defensive medtech rarely this oversold. -11.1% 30D looks like forced selling. |
| 🔍 RESEARCH | BNTX | RSI 23 capitulation — validate mRNA demand thesis before buying the dip. |
| 🔍 WATCH | TMO, A, NVO | RSI 31-34, approaching oversold. Quality names need stabilization signal. |
| 🔍 WATCH | ISRG, DXCM | RSI 38-40, surgical/medtech weakening. Watch for RSI <35 entry trigger. |
| 🔍 WATCH | IONS, INCY, IQV | RSI 38-39, drifting lower. Monitor for oversold entry. |
| 📈 ACCUMULATE | LLY | RSI 45, GLP-1 king stable at $999. Holding far better than NVO. |
| 📈 ACCUMULATE | LEGN, CRSP, NTLA | Gene editing/therapy names recovering. LEGN +10.1% 7D, NTLA +12.3% 30D. |
| 📈 ACCUMULATE | VRTX | RSI 60, quietly leading pharma. +8.2% 30D, only -4.0% from high. |
| 🔒 HOLD | ABBV, AMGN, REGN, BIIB, GILD | Large-cap pharma RSI 50-57 — stable, defensive, boring. Golden crosses intact. |
| 🔒 HOLD | XBI, IBB, IBBQ, LABU | Sector ETFs neutral RSI 49-54. No conviction signal either way. |
| 🔒 HOLD | ALNY, BMRN, EXAS, ILMN | Mid-cap genomics/diagnostics RSI 42-56. Stable. |
| ⚠️ AVOID | EDIT | RSI 67, +49.2% 30D on a sub-$3 micro-cap. Extended, high reversal risk. |
| ⚠️ AVOID | PTGX | RSI 67, +16.2% 30D — extended near highs. |
| ⚠️ AVOID | MRNA | RSI 64, +38.4% 30D, +89.3% 3M — parabolic, don't chase. |
| ❌ DON'T BUY | DNA | RSI 34, -32.2% 30D, -36.0% 3M, -63.9% from high. Falling knife. |
| ❌ DON'T BUY | RXRX | RSI 40, -24.9% 3M, -52.1% from high. Structural decline. |
| ❌ DON'T BUY | SRPT | RSI 47 but -82.9% from 52-week high. Gene therapy in deep structural distress. |
| — | BLUE, SWTX | No data available |
What Changed (vs 2026-03-10 scan)
| Change | Detail |
|---|---|
| TMO deepening | RSI dropped from 35 to 33, now -12.0% below SMA50. Life sciences tools selloff intensifying. |
| CRSP sharp pullback | -11.6% 7D drop, RSI fell from 45 to 41. Death cross now active — gene editing bounce fading. |
| MRNA extends further | 30D gain expanded from +35.7% to +38.4%, RSI 64. Divergence with BNTX (RSI 23) remains extreme. |
| ABBV ticks up | RSI 50 from 49, price $227.75 vs $227.01. Marginally stronger, golden cross intact. |
| Tools group still oversold | DHR (29), MDT (27), A (31), TMO (33) — all remain in or near oversold territory. No bounce yet. |
| BNTX unchanged | Still capitulating at RSI 23, -23.3% 30D. No stabilization. |
Key Discoveries
| Discovery | Implication |
|---|---|
| Four life sciences tools names (DHR RSI 29, MDT RSI 27, A RSI 31, TMO RSI 33) remain in coordinated selloff — no bounce | Sector-wide de-rating deepening. Best entry in tools in months if macro stabilizes. |
| MRNA +89.3% 3M while BNTX -12.6% 3M | mRNA market picking winners. MRNA pipeline diversification working; BNTX one-trick COVID thesis failing. |
| LLY -1.4% 30D vs NVO -20.6% 30D | GLP-1 leadership consolidating around LLY. NVO death cross active, -53% from highs. |
| CRSP pulled back -11.6% 7D, death cross now active | Gene editing bounce may be fading. CRSP -9.8% below SMA20 — watch for further deterioration. |
| IQV -17.1% below SMA50 | Deepest SMA50 gap in the tools/services group. CRO business under severe pressure. |
Mistakes (Don't Repeat)
| Mistake | Lesson |
|---|---|
| Waiting too long on oversold tools names | DHR/MDT have been oversold for multiple sessions. Set entry levels and execute if thesis intact. |
Open Questions
- Is BNTX RSI 23 a buy or a value trap? Need to assess mRNA pipeline beyond COVID.
- MDT rarely this oversold — GLP-1 weight loss reducing surgical volumes, or pure rotation?
- DHR + A + TMO + MDT still oversold together — buy the basket or wait for macro stabilization?
- MRNA +89.3% 3M — what changed? Pipeline catalyst, partnership, or short squeeze? Need deep dive.
- CRSP death cross + -11.6% 7D — is the gene editing recovery over?
- IQV at -17.1% below SMA50 — structural CRO industry headwind or idiosyncratic?
Related
10 eventsNo direct external sources are attached to this read.